A Rare Case of Ixazomib-Induced Cutaneous Necrotizing Vasculitis in a Patient with Relapsed Myeloma

A Rare Case of Ixazomib-Induced Cutaneous Necrotizing Vasculitis in a Patient with Relapsed Myeloma

Ixazomib is the only oral proteasome inhibitor used in relapsed/refractory myeloma. Cutaneous side effects due to ixazomib have been documented in the literature; however, cutaneous necrotizing vasculitis is extremely rare. We describe a case of a 74-year-old man with relapsed multiple myeloma who w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Case reports in hematology 2019-10, Vol.2019 (2019), p.1-4
Hauptverfasser: Sonnier, George, Dahshan, Deena, Shenouda, Mina, Katz, Heather, Lebowicz, Yehuda
Format: Artikel
Sprache:eng
Schlagworte:
Bone marrow
Care and treatment
Carfilzomib
Case Report
Case reports
Complications and side effects
Dermatology
Dexamethasone
Diseases
Drug dosages
Edema
Fractures
Leukemia
Lymphoma
Multiple myeloma
Patients
Peripheral neuropathy
Plasma
Relapse
Skin
Steroids
Vasculitis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Ixazomib is the only oral proteasome inhibitor used in relapsed/refractory myeloma. Cutaneous side effects due to ixazomib have been documented in the literature; however, cutaneous necrotizing vasculitis is extremely rare. We describe a case of a 74-year-old man with relapsed multiple myeloma who was started on ixazomib, lenalidomide, and dexamethasone. He developed several skin lesions that were biopsied and revealed cutaneous necrotizing vasculitis. Ixazomib was held with resolution of the vasculitic lesions and restarted with dexamethasone to 20 mg on the day of treatment and 20 mg dose the day after treatment.
ISSN:2090-6560
2090-6579
DOI:10.1155/2019/6061484